Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes by Eric A. Benson et al.
ORIGINAL RESEARCH
published: 26 April 2016
doi: 10.3389/fphar.2016.00111
Frontiers in Pharmacology | www.frontiersin.org 1 April 2016 | Volume 7 | Article 111
Edited by:
Olavi R. Pelkonen,
University of Oulu, Finland
Reviewed by:
Paavo Honkakoski,
University of Eastern Finland, Finland
Amal Kaddoumi,
University of Louisiana at Monroe,
USA
*Correspondence:
Eric A. Benson
eabenson@iu.edu
Specialty section:
This article was submitted to
Drug Metabolism and Transport,
a section of the journal
Frontiers in Pharmacology
Received: 27 January 2016
Accepted: 12 April 2016
Published: 26 April 2016
Citation:
Benson EA, Eadon MT, Desta Z, Liu Y,
Lin H, Burgess KS, Segar MW,
Gaedigk A and Skaar TC (2016)
Rifampin Regulation of Drug
Transporters Gene Expression and the
Association of MicroRNAs in Human
Hepatocytes.
Front. Pharmacol. 7:111.
doi: 10.3389/fphar.2016.00111
Rifampin Regulation of Drug
Transporters Gene Expression and
the Association of MicroRNAs in
Human Hepatocytes
Eric A. Benson 1*, Michael T. Eadon 1, Zeruesenay Desta 1, Yunlong Liu 2, Hai Lin 2,
Kimberly S. Burgess 3, Matthew W. Segar 2, Andrea Gaedigk 4 and Todd C. Skaar 1
1Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA,
2Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA, 3Department
of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA, 4Division of Clinical
Pharmacology, Toxicology and Therapeutic Innovation, Children’s Mercy Kansas City and School of Medicine, University of
Missouri-Kansas City, Kansas City, MO, USA
Membrane drug transporters contribute to the disposition of many drugs. In human liver,
drug transport is controlled by two main superfamilies of transporters, the solute carrier
transporters (SLC) and the ATP Binding Cassette transporters (ABC). Altered expression
of these transporters due to drug-drug interactions can contribute to differences in drug
exposure and possibly effect. In this study, we determined the effect of rifampin on gene
expression of hundreds of membrane transporters along with all clinically relevant drug
transporters.
Methods: In this study, primary human hepatocytes (n = 7 donors) were cultured and
treated for 24 h with rifampin and vehicle control. RNAwas isolated from the hepatocytes,
mRNA expression was measured by RNA-seq, and miRNA expression was analyzed by
Taqman OpenArray. The effect of rifampin on the expression of selected transporters
was also tested in kidney cell lines. The impact of rifampin on the expression of 410
transporter genes from 19 different transporter gene families was compared with vehicle
control.
Results: Expression patterns of 12 clinically relevant drug transporter genes
were changed by rifampin (FDR < 0.05). For example, the expressions of
ABCC2, ABCB1, and ABCC3 were increased 1.9-, 1.7-, and 1.2-fold, respectively.
The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1,
SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific
microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#,
and SLC22A9/miR-20; r < −0.79; p < 0.05). Seven hepatic drug transporter
genes (SLC22A1, SLC22A5, SLC15A1, SLC29A1, SLCO4C1, ABCC2, and ABCC4),
whose expression was altered by rifampin in hepatocytes, were also present
in a renal proximal tubular cell line, but in renal cells rifampin did not alter
their gene expression. PXR expression was very low in the kidney cells; this
may explain why rifampin induces gene expression in a tissue-specific manner.
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Conclusion: Rifampin alters the expression of many of the clinically relevant hepatic
drug transporters, which may provide a rational basis for understanding rifampin-induced
drug-drug interactions reported in vivo. The relevance of its effect on many other
transporters remains to be studied.
Keywords: rifampin, drug transporter, gene expression, microRNA, human hepatocyte, ChIP-Seq, PXR binding
site, RNA sequencing
INTRODUCTION
The transport of drugs in and out of tissues and cells is now
recognized as an important factor in drug efficacy and toxicity
(International Transporter et al., 2010; Hillgren et al., 2013). Drug
transport occurs at key sites including the liver, kidney, intestine,
and blood-brain barrier to regulate drug and/or metabolite
distribution (International Transporter et al., 2010; Hillgren et al.,
2013). Understanding the regulation of drug transporter gene
expression is important to improve drug efficacy and toxicity,
especially for the many drugs transported into and out of the
liver. Drug transport into and out of the liver is controlled by
two superfamilies of transporters, the solute carrier transporters
(SLC) and the ATP Binding Cassette transporters (ABC). Among
these transporters, 32 have currently been designated as clinically
relevant drug transporters (pharmADME.org; International
Transporter Consortium; International Transporter et al., 2010;
Hillgren et al., 2013). For most of these transporters, gene
expression has not been studied in primary human hepatocytes
to assess the impact of rifampin.
Rifampin is commonly used to treat tuberculosis worldwide.
It is well-known to induce the expression of many of the
cytochrome P450 drug metabolism genes. It is also known to
regulate the gene expression of several ABC drug transporters,
but its effects on many of the transporters is yet unknown
(Stapelbroek et al., 2010; Peters et al., 2011; Vilas-Boas et al.,
2013; Weiss and Haefeli, 2013). Several clinically significant
rifampin-induced drug-drug interactions have been documented
(Niemi et al., 2003; Baciewicz et al., 2013). At least some of
the rifampin effect is due to its binding to and activation
of the pregnane X receptor (PXR). PXR is a transcription
factor that regulates the expression of several of the ABC
transporter genes (Mottino, 2008). In addition, rifampin can
also regulate transporter expression indirectly by regulating
microRNAs (miRNAs), which target the transporter mRNAs
(Haenisch et al., 2011). miRNAs are short RNA sequences
that regulate mRNA function by degrading the target mRNAs
or blocking the mRNA translation. Rifampin induces hepatic
expression of many miRNAs (Ramamoorthy et al., 2013),
and miRNAs have been shown to regulate drug transporter
expression and translation (Haenisch et al., 2011; Zhu et al.,
2011; Bang and Thum, 2012), supporting the possibility
that miRNAs mediate some of the effects of rifampin on
transporter expression. In fact, this has been shown to
be true where rifampin induces miRNA-379 expression in
the HepG2 human liver cancer cell line and this miRNA
subsequently down-regulates ABCC2 protein levels (Haenisch
et al., 2011).
In this report, we addressed three aims. First, we determined
the effect of rifampin on the expression of the 32 clinically
relevant drug transporter genes in primary human hepatocytes.
Next, we determined the association of the rifampin-mediated
changes in transporter expression with the rifampin-mediated
induction of miRNA expression. Lastly, we evaluated whether the
effects of rifampin on several drug transporters in hepatocytes has
any tissue specificity. Our results demonstrate the wide-reaching
effects of rifampin on the expression of many transporter genes
relevant to drug metabolism and disposition.
METHODS
Human Hepatocytes, Drug Treatment, RNA
Isolation, and miRNA Profiling
Our studies analyzed the RNA expression data collected by
the studies done by Ramamoorthy et al. (2013). In those
studies, “human hepatocytes from seven different subjects
were obtained from CellzDirect (Durham, NC).” The primary
human hepatocytes were grown on collagen coated plates and
treated with rifampin (10 µM) or vehicle (methanol, 0.01%)
for 24 h. Each culture from a different individual subject was
treated as a biologic replicate (n = 7). In vitro studies were
performed within 72–120 h from the time of hepatocyte isolation.
Total RNA and miRNA were isolated with a miRNeasy kit
(Qiagen, Valencia, CA). miRNAs (754) were analyzed using
the Taqman OpenArray Human miRNA Panel in technical
duplicates (each sample run on two OpenArrays). Global
mRNA expression was measured by RNA-seq conducted on
the SOLiD4 system (Life Technologies, Inc, Carlsbad, CA).
The hepatocyte tissues were purchased commercially, and were
de-identified. These studies were not deemed human subject
research. CellzDirect was purchased by another company, and
specific demographic or clinical information on the donors was
not transferred in the transition and the information could not
be retrieved.
miRNA Bioinformatics
The miRNA bioinformatic analysis was re-performed from the
original analysis done by Ramamoorthy et al. (2013). For the
technical duplicate values, the CT values were averaged. If a
miRNA had no value for both technical replicates, then it was
assigned the highest CT value of 40. In rare cases, if one technical
duplicate detected the miRNA and the other technical duplicate
was undetectable, the detectable value was used. To determine
which miRNAs to include in the study, we selected only those
with at least four of the seven control samples or four of the seven
rifampin treated samples with average CT values < 35. All the
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small nuclear RNA, U6 and RNUs, were removed. The remaining
333 miRNAs were Quantile normalized using PARTEK software.
Quality control analysis after each normalization step included
the visual evaluation of the histograms followed by principal
component analysis (PCA) to identify systematic variations
caused by various factors such as OpenArray runs. Normalized
data were analyzed by ANOVA using a mixed effect model.
RNA sequencing Analysis
Our studies used the data processing, quality assessment,
sequence alignment, and gene expression analysis that was
previously performed and published by Ramamoorthy et al.
(2013). As previously described for quality control, low quality.
Briefly, RNA sequencing reads were removed including reads of
less than 35 bases, or having a quality score of 20 or less. RNAwas
considered expressed if at least 10 reads were present after counts
per million normalization.
Treatment and control groups were compared using the log2
transformed fold-change values. Of note, six data points in the
transporter genemRNA expression data were undetectable. Since
a zero cannot be used in the log2 transformed fold-change
calculations, the zero values were replaced with the minimum
read numbers. The resultant p-values of the 410 transporters were
corrected using a Benjamini and Hochberg’s false discovery rate
correction. A fold-change of one represents no change; a two-fold
change is a doubling of the expression level.
Correlations of the rifampin effects on the expression of
two transporter genes were performed using the Spearman
rank correlations on the log2 transformed fold-change values.
Correlations of the rifampin effect on specific gene expression
with specific miRNA expression were also performed using the
Spearman rank correlations on the log2 transformed fold-change
using the delta CT values for the miRNA expression.
Selection of Transporters
All human transporter genes were identified using the University
of California Santa Cruz reference genome using the following
inputs: http://genome.ucsc.edu/cgi-bin/hgTables, criteria- group:
genes and gene prediction, track: RefSeq Genes, table: RefGene,
assembly: feb. 2009 (GRch37/hg19), clade: mammal, genome:
human, region: genome, output format: selected fields from
primary and related tables, click get output button, then on
the next screen, check both- Name [name of gen (usually
transcript_id from GTF)], and name 2 [alternate name(e.g.,
gene_id from GTF)] and then click get output. Selected
transporters evaluated in our study were queried from this
UCSC gene list. These human transporters were selected using
a combination of literature, pharmADME.org, and NIH NCBI
Gene using the term transporter, and using terms transporter,
influx transporter, eﬄux transporter. Transporter gene families
were chosen based on possible relevance to drug metabolism or
clinical relevance.
Culture and Rifampin Treatment of Renal
Cells
Normal human proximal tubular kidney (NHPTK) cells were
a gift from the Robert L. Bacallao Laboratory (Herbert et al.,
2013). NHPTK cells are primary renal cells from a single donor
immortalized with human telomerase plasmid transfection
and maintained in REGM media (Lonza, Basel, Switzerland)
supplemented with 10% fetal bovine serum (HyClone) to
maintain their renal phenotype. NHPTK cells were diluted to
20–30% confluence three times a week and maintained at 37◦C
in 95% humidified atmosphere with 5% CO2. All in vitro studies
were performed on cells in passages 6 through 9 (corresponds to
passage 3 through 6 following immortalization). Cultures from
each passage were treated as biologic replicates (n = 4). NHPTK
cells were treated for 24 h with rifampin (10 µM) or with the
vehicle control of methanol (0.01%).
Quantitative Real-Time PCR of Renal Cells
Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed to measure the level of expression of CYP3A4,
GAPDH, and other transporter genes in NHPTK cells. Since,
the PXR expression was at the limit of detection in NHPTK
cells, we measured PXR in HepG2 cells as a positive control
to verify that are assay could detect the low quantity of PXR
found in HepG2 cells. A total of 1 million cells were pelleted
following rifampin or vehicle treatment, washed in ice-cold PBS,
centrifuged to remove PBS, and stored at −80◦C until RNA
isolation. Total RNAwas extracted using themiRNeasy PlusMini
Kit (Qiagen, Hilden, Germany) following the manufacturer’s
protocol. RNA quality assessment and quantification were
conducted using the optical spectrometry 260/280 and 260/230
nm ratios. Subsequently, mRNA was reverse transcribed to
cDNA using the Bio-Rad iScript Reverse Transcription Kit
(Bio-Rad, Hercules, CA). The final concentration of cDNA
was 25 ng/ml. qRT-PCR was performed with TaqMan Gene
Expression Assays (Bio-Rad) for CYP3A4, using commercially
obtained primers on the Bio-Rad iCycler RT-PCR system as
previously described (Eadon et al., 2013). qRT-PCR for all
other genes, including GAPDH as an endogenous control, was
performed using custom made primers (Life Technologies) and
iTaq Universal SYBR Green (Bio-Rad) on the Bio-Rad iCycler
RT-PCR system. Primer sequences are provided in Supplemental
Table 1. Reactions were carried out in 20 µl volumes, which
consisted of: 10 µl SYBR green, 4 µl cDNA, 0.4 µl of each
primer (10 µM stock), and 5.2 µl of water. The RT-PCR
reactions were run in triplicate. The thermocycler parameters
were 95◦C for 30 s, 40 cycles of 95◦C for 15 s and then an
annealing temperature for 30 s (provided in Supplemental Table
1), with ramping speeds of 1.6–1.98 degrees ◦C/s and a melt
curve. The CT threshold and baseline for each experiment
were set automatically by the Bio-Rad software. The delta-delta
(11CT) method was used to obtain the relative expression of
each gene for samples treated with rifampin or vehicle. Each
sample’s gene expression of interest was first subtracted from its
GAPDH expression to determine its 1CT. The 1CTcontrol was
then subtracted from the 1CTrifampin to determine the 11CT.
Fold-changes of the rifampin treatments as compared to the
controls were determined by the formula: fold change = 211CT.
Gene expression for each condition is given as a fold-change ±
SEM relative to the control where the SEM was calculated from
individual11CTs of the 4 biologic replicates for each condition.
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Statistical significance was assessed based on a student’s t-test
between conditions.
In silico ChIP-Seq PXR Binding Site
Analysis
A publically available chromosome immunoprecipitation DNA
sequencing (ChIP-Seq) database available from Smith et al.
(2014) was analyzed in silico for PXR binding sites within the 410
transporter genes in this study (Smith et al., 2014). This ChIP-Seq
dataset analyzed the PXR binding in rifampin treated vs. DMSO
vehicle treated HepG2 cells.
Accession Numbers
The raw RNA-seq data have been made publically available
through NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number GSE79933
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79933).
The miRNAOpenArray data have been made publically available
at http://compbio.iupui.edu/group/6/pages/rifampin.
RESULTS
Regulation of Membrane Transporters by
Rifampin
A total of 410 transporter genes from 19 transporter gene
families were selected for analysis in the primary hepatocytes.
Two hundred sixty-seven of the genes were in the ABC and SLC
superfamilies of transporters. Thirty-four of the 267 are drug
transporters that are considered to be clinically important for
drug disposition (International Drug Transporter Consortium
and/or PharmADME.org; International Transporter et al., 2010;
Hillgren et al., 2013). Of the 32 transporters designated as
“clinically relevant drug transporters” by the International
Transporter Consortium (Table 1), we expected at least 18 to
be expressed in the hepatocytes (Hillgren et al., 2013). All
18 expected drug transporter genes were indeed found to be
expressed in every donor sample; we also found six additional
transporters that were previously not reported to be expressed in
the liver (Table 2). The expression of 12 of these drug transporter
genes was modulated in the hepatocytes by rifampin (Table 2).
Rifampin induced the expression of 9 of the 12 drug transporter
genes and the expression of three transporters was reduced. The
results of the other 16 families of transporters (143 genes) we have
characterized are provided in Supplemental Table 2.
Rifampin altered the expression of 62 of the 267 (∼23%) solute
carrier (SLC) superfamily genes (Supplemental Table 2). The
fifteen SLC genes with the highest changes in expression levels
are shown in Figures 1A,B. The expression of three out of the
five (60%) detected genes of the SLCO family were also altered by
rifampin (Supplemental Table 2). PXR has been shown to regulate
SLCO2B1 and SLCO1B1, but the expression of only SLCO2B1
increased (1.73-fold) in our study. In addition, rifampin altered
the expression of 12 of the 38 (32%) ATP-binding cassette (ABC)
superfamily transporter genes (Supplemental Table 3). Eleven of
these ABC genes were induced as shown in Figure 1C, and one
(ABCA8) was reduced (Supplemental Table 2).
TABLE 1 | Clinically important drug transporters.
Influx Gene name Efflux Gene name Influx/Efflux Gene name
*MCT1 SLC16A1 *MDR1 ABCB1 *ENT1 SLC29A1
*PEPT1 SLC15A1 *BCRP ABCG2 *ENT2 SLC29A2
*OCT1 SLC22A1 *MRP2 ABCC2 *OSTalpha SLC51A
*OAT2 SLC22A7 *MRP3 ABCC3 *OSTbeta SLC51B
*OATP4C1 SLCO4C1 *MATE1 SLC47A1 *OCTN2 SLC22A5
*OATP2B1 SLCO2B1 *MRP4 ABCC4
*NTCP SLC10A1 *MRP6 ABCC6 OAT4 SLC22A11
*OATP1B3 SLCO1B3 *BSEP ABCB11 OCTN1 SLC22A4
*OATP1B1 SLCO1B1 *MRP5 ABCC5
*OAT7 SLC22A9
MATE2-K SLC47A2
ASBT SLC10A2
PEPT2 SLC15A2
URAT1 SLC22A12
OAT3 SLC22A8
OAT1 SLC22A6
OCT2 SLC22A2
OATP1A2 SLCO1A2
Clinical importance of drug transporters as determined by the International Transporter
Consortium, and pharmADME.org. *(Bold) The 24 genes with detectable expression in
the primary human hepatocytes.
Correlations of the Effect of Rifampin on
Gene Expression
We next tested whether there were correlations in the effect of
rifampin on the expression of drug transporter and cytochrome
P450 (CYP) genes. Since each hepatocyte culture replicate was
from a different donor, we considered each replicate a separate
individual. There were nine pairs of drug transporters that were
positively correlated (FDR< 0.05; Figure 2; all CYP/Transporter
gene expression correlations are found in Supplemental Table 3),
i.e., each pair of genes was upregulated (r > 0.79) upon rifampin
treatment. We also correlated the rifampin effects on the drug
transporters with rifampin effects on CYP gene expression. There
were seven positive correlations (FDR < 0.05; Figure 3; for the
correlations of all CYP/Transporter genes see Supplemental Table
4). Interestingly, four were correlations with CYP4F2 (SLCO2B1,
SLC29A1, SLC47A1, and SLCO4C1).
Correlation between miRNA Induction and
Changes of Clinically Relevant Drug
Transporter Expression
We have previously shown that rifampin induces the expression
of several miRNAs in hepatocytes (Ramamoorthy et al., 2013).
To identify drug transporters that may be modulated by these
miRNAs, we determined the correlations between rifampin
induction of miRNAs and the rifampin effect on drug transporter
gene expression. The direct effects of the miRNAs on gene
expression would be expected to downregulate transporter
expression; however, since miRNAs could also have indirect
effects and induce the expression of the drug transporter genes,
we searched for both positive and negative correlations. We
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TABLE 2 | Rifampin-induced changes in gene expression of clinically relevant drug transporters.
Common name Gene name Fold change p-value FDR Example of substrates*
OSTbeta SLC51B 12.67 1.20E-113 4.90E-111 Bile acids, conjugated steroids
MRP2 ABCC2 1.85 3.56E-23 2.92E-21 Chemotherapy, statin, antepileptics, tamoxifen, DMARDs, antidepressants,
clopidogrel, anti-retroviral
MDR1 ABCB1 1.72 6.63E-18 3.02E-16 Chemotherapy, statin, antepileptics, tamoxifen, DMARDs, antidepressants,
clopidogrel, anti-retroviral
OATP2B1 SLCO2B1 1.73 2.34E-16 8.73E-15 Fexofenadine, montelukast, grapefruit, orange juice, apple juice, endogenous steroids
MRP6 ABCC6 1.65 5.82E-14 1.84E-12 Thalidomide, docetaxel
OATP1B3 SLCO1B3 −1.57 2.15E-11 5.18E-10 Irinotecan, docetaxe, myophenolate, statin, methotrexate
OATP4C1 SLCO4C1 1.46 2.84E-07 3.88E-06 Estrone 3-sulfate
MATE1 SLC47A1 1.37 2.64E-06 2.84E-05 Meformin, trimethoprim
ENT1 SLC29A1 1.38 4.68E-06 4.80E-05 Gemcitabine, paclitaxe, gemcitabine, peginterferon, ribavirin
OAT7 SLC22A9 −1.34 9.76E-05 0.0007 Methotrexate
PEPT1 SLC15A1 −1.27 5.01E-04 0.0031 Statin, oseltamivir
MRP3 ABCC3 1.18 0.0098 0.038 Cisplatin, MTX, doxorbuicn, cyclophosphamide, clopidogrel, codiene, morphine,
etoposide
OSTalpha SLC51A 1.21 0.014 0.050 Bile acids, conjugated steroids
BCRP ABCG2 1.18 0.015 0.054 Antiepileptics, MTX, statin, anti-retrovirals, tecans, anti-neoplastics (irinotecan,
platinum, anthracycline, taxane) acetaminophen, uric acid
OCT1 SLC22A1 −1.16 0.019 0.060 Morphine, metformin, tramadol, antiemetics, dopamine agonist, antiretrovirals,
sorafinib
OAT2 SLC22A7 −1.15 0.040 0.11 Fluoropyrimidine, zidovudine
MRP5 ABCC5 1.17 0.066 0.16 Antiepileptics, irinotecan
MRP4 ABCC4 1.17 0.090 0.21 cisplatin, antiretroviral, bisphosphonates, MTX, acetaminophen, azathioprine,
mercaptopurine
NTCP SLC10A1 −1.08 0.21 0.39 Bile acids
OCTN2 SLC22A5 −1.08 0.30 0.51 Imatinib, oxaliplatin
BSEP ABCB11 −1.07 0.32 0.55 Statin
OATP1B1 SLCO1B1 1.04 0.57 0.74 Simvastatin, statin, rifampin, irinotecan, methotrexate, thyroid, estrone sulfate,
angiotensin receptor blocker, MTX, caspofungin, ace inhibitor
MCT1 SLC16A1 1.03 0.61 0.78 Lactate
ENT2 SLC29A2 −1.03 0.89 0.94 Gemcitabine, thiopurine
Primary human hepatocytes were treated with 10 µM Rifampin or vehicle for 24 h. Fold-change is the ratio of gene expression treatment/control. A fold-change equal 1 is defined as
no change, and a fold change of 2 is defined as 2x the expression. FDR, False Discovery Rate. *Cited from PharmGKB.org.
identified 14 highly correlated negative associations (Table 3; for
the correlations of the all transporter/miRNAs gene expression
see Supplemental Table 5). Three miRNAs, miR-320, miR-616,
and miR-95, each correlated with two different drug transporters.
Three drug transporters, ABCB11, ABCC4, and ABCC5 were
negatively correlated with two different miRNAs each. Based
on the bioinformatics tools we employed, none of these were
predicted to be direct effects. Only three rifampin-induced
miRNAs were predicted to bind to drug transporters. Target Scan
predicted miRNA binding of miR-335 to SLC29A2, miR-200b# to
SLCO1B1, and miR-616 to SLCO1B1. However, neither of these
transporters genes expression were altered by rifampin.
We identified 18 highly positive correlations between the
rifampin effects on miRNAs and its effects on drug transporter
expression levels (Table 3; Supplemental Table 5). miR-660
positively correlated with seven different transporters, miR-766
positively correlated with three transporters, and miR-886-3p
and let-7g positively correlated with two transporters. None of
the rifampin-induced miRNAs were predicted to bind to any of
the rifampin-regulated drug transporters.
Rifampin’s Modulation of Drug Transporter
Gene Expression is Tissue Specific
Many of the drug transporters that we detected in the
hepatocytes are also expressed in other tissues, including the
kidney (Hillgren et al., 2013). Thus, we determined if rifampin
demonstrated any tissue specificity by regulating the same
transporters in human kidney cells. Normal human proximal
tubular kidney (NHPTK) cells were treated with rifampin
analogously to primary hepatocytes, and gene expression was
measured. Seven transporters were selected based on their
differential expression in hepatocytes and their renal proximal
tubular relevance. Expression of SLC22A1, SLC22A5, SLC15A1,
SLC29A1, SLCO4C1, MRP2, and MRP4 was detected, but did not
change significantly following rifampin treatment (Supplemental
Figure 1A; statistics are provided in Supplemental Table 6).
CYP3A4 expression was low in NHPTK cells with raw CT
values between 35 and 37. Expression was not significantly
elevated following rifampin treatment (Supplemental Figure 1B).
As CYP3A4 is PXR dependent, gene expression of NR1I2 (PXR)
was also measured in NHPTK cells and compared to NR1I2
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FIGURE 1 | SLCs (including SLCOs) and ABCs mRNA expressions regulated by rifampin with FDR < 0.05. (A) Induction of SLCs by rifampin by fold change
(fold change represented as rifampin/control) (FDR < 0.05); the top 15 SLCs are shown. (B) Reduction of SLCs by rifampin by fold change (fold change represented
as control/rifampin) (FDR < 0.05); the 15 most reduced SLCs are shown. (C) Rifampin induced 11 ABC transporter genes based on fold change (rifampin/control)
with FDR < 0.05. A fold change equal to 1 is defined as no change, and a fold change of 2 is defined as 2x the expression.
expression in a positive control cell line, HepG2 cells. Since we
expected NR1I2 expression to be much lower than hepatocytes,
we used HepG2 as a positive control, which is known to have
relatively low NR1I2 expression levels (Gerets et al., 2012). The
expression of NR1I2 was much lower in NHPTK cells when
compared to HepG2 (Supplemental Figure 1C).
38 Transporters have Rifampin Induced
PXR Binding Sites
Utilizing a publically available ChIP-Seq database from Smith
et al. (2014), Figure 4 illustrates our in silico analysis of this
dataset. The 410 transporter genes were mapped to Ensembl
annotation. The transcription start site (TSS) was located for
each gene and a promoter region was defined as ± 2 kilobases
from TSS of each gene. From the ChIP-Seq dataset, 6302 PXR
peaks were identified in the rifampin treated HepG2 cells and
1157 PXR peaks in DMSO treated HepG2. PXR peaks were
extracted only if uniquely found in rifampin treated HepG2
vs. DMSO vehicle. The remaining 6063 unique rifampin peaks
were compared for overlap with the 410 promoter regions of
the transporters. 58 of the 410 transporter genes’ promoter
regions were identified to have PXR binding sites. Table 4
illustrates the PXR binding site for one isoform of each gene
transcript, while Supplemental Table 7 provides a list of the PXR
binding site analysis for all gene transcript isoforms. Thirty three
members of the SLC (SLC10A7, SLC16A3, SLC17A5, SLC1A4,
SLC20A1, SLC20A2, SLC22A15, SLC22A3, SLC23A2, SLC25A1,
SLC25A10, SLC25A11, SLC25A22, SLC25A4, SLC25A42,
SLC25A5, SLC26A2, SLC29A1, SLC2A1, SLC2A10, SLC30A10,
SLC37A3, SLC39A7, SLC39A8, SLC3A2, SLC41A2, SLC43A1,
SLC47A1, SLC5A11, SLC5A3, SLC5A9, SLC7A5, and SLCO2B1),
and 7 members of the ABC (ABCA2, ABCA3, ABCA9, ABCB4,
ABCC10, ABCC2, and ABCC3) superfamily of transporters have
PXR binding sites. Five of the clinically relevant drug transporter
genes, ABCC2, ABCC3, SLC29A1, SLC47A1, and SLCO2B1 were
found to have PXR peaks within their promoter regions.
DISCUSSION
Our study has several important first-time characterizations
of rifampin’s direct and indirect regulation of membrane
transporters. First, rifampin regulates the gene expression of
many members of the two major superfamilies (ABC and
SLC) involved with clinically relevant drug transport. Second,
the modulation of rifampin of transporter gene expression
is associated with changes in miRNA expression. Third, we
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FIGURE 2 | The significant correlations between the expression of clinically relevant transporter genes that were regulated by rifampin. The expression
[represented by log2fold change (Log2FC)] after rifampin treatment) was correlated for all 410 transporter genes. Only the significant correlation (p < 0.05 by
Spearman correlation) are shown for transporters regulated by rifampin with an FDR <0.05. Spearman correlation was performed because an assumption of normal
distribution could not be made.
demonstrated that the effect of rifampin on transporter gene
expression is tissue-specific. To the best of our knowledge,
this study provides the first global characterization of rifampin
induction of drug transporter gene expression.
Our studies demonstrate that rifampin treatment induces
the gene expression of many members of the SLCO, SLC, and
ABC transporter families. Twelve ABC transporter genes were
regulated either directly or indirectly by rifampin; of these 12
ABC transporters genes, five of have previously been shown to be
regulated by rifampin (Nishimura et al., 2002; Teng et al., 2003;
Stapelbroek et al., 2010; Vilas-Boas et al., 2013;Weiss and Haefeli,
2013; Williamson et al., 2013) and two of the three ABC genes
with the smallest p-values in our data set were drug transporters
(ABCC2, and ABCB1). ABCC2 and ABCB1 have been shown
to be induced by the nuclear receptor, PXR (Geick et al., 2001;
Kast et al., 2002). Our analysis of a publically available ChIP-Seq
dataset confirmed that ABCC2 has a PXR binding site within the
promoter region. ABCB1 was not found to have a PXR binding
site by our in silico ChIP-Seq analysis. PXR mediates at least part
of the rifampin effects through direct binding to rifampin and
nuclear localization (Stapelbroek et al., 2010; Honorat et al., 2011;
Roques et al., 2013; Vilas-Boas et al., 2013; Weiss and Haefeli,
2013; Williamson et al., 2013). We likely did not identify the
ABCB1 PXR binding site within the promoter region due to
defining the promoter region using the common convention of
± 2 kilobases around the TSS. In Kast et al. (2002), the ABCB1
PXR binding site was over 7 kilobases from the TSS.
In the SLC family, the expression of 44 transporters were
induced by rifampin. The most highly induced SLC transporter
gene was the clinically relevant drug transporter SLC51B
(OSTbeta; >12-fold), which is a newly recognized transporter
that heterodimerizes with OST alpha and transports bile acids
and conjugated steroids (Ballatori et al., 2013). For comparison,
CYP3A4 was induced 22-fold (Ramamoorthy et al., 2013). We
used a similar method of analyzing the data as Ramamoorthy
et al., and with the same RNA-seq data set, CYP3A4 was induced
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FIGURE 3 | The significant correlations between the expression of drug metabolism genes and clinically relevant transporter genes that are regulated
by rifampin. The expression [represented by log2fold change (Log2FC)] after rifampin treatment was correlated between all CYP and 410 transporters genes. The
figure illustrates, the seven significant positive and one significant negative correlations between the expression of CYP and drug transporter genes that were
regulated by rifampin with an FDR < 0.05. These were the only correlations with a p < 0.05 by Spearman correlation. Spearman correlation was performed because
an assumption of normal distribution could not be made.
22-fold in our analysis as well. None of the SLC drug transporter
genes (excluding SLCOs) have previously been shown to be
induced by PXR or rifampin (Dixit et al., 2007). Our ChIP-Seq
analysis identified that 33 SLC genes (Table 4 and Supplemental
Table 7) had PXR binding sites. The two clinically relevant drug
transporter SLC genes with a PXR binding peak identified in their
promoter region were SLC29A1, and SLC47A1. The genes were
induced by rifampin 1.38- and 1.37-fold (p < 0.05) respectively.
SLC51B was not one of them. Although PXR and rifampin
regulation of SLC transporters was mentioned in a review article
(Ihunnah et al., 2011), we have been unable to find any published
data supporting their statement for rifampin or PXR, but our
ChIP-Seq analysis suggests that the rifampin induction of much
of the SLC gene expression may be through other transcription
factors (Rae et al., 2001; Hagenbuch and Meier, 2004).
In the SLCO family, two transporter genes (SLCO4C1 and
SLCO2B1) were induced by rifampin; both are clinically relevant
drug transporter genes. Neither of these SLCOs expressions have
been previously shown to be altered by rifampin or PXR. Based
on our ChIP-Seq data, SLCO2B1 has a PXR binding site in their
promoter.
Overall, five of the 12 rifampin induced clinically relevant
transporters have PXR binding sites by ChIP-Seq analysis. With
an additional sixth gene, ABCB1, having a published report of a
PXR binding site, half of the rifampin induction of the clinical
relevant transporter gene expression in this study was likely in
part due to PXR activation. Our data suggest that a smaller
portion of the induction of all ABCs, SLCs, and SLCOs gene
expressions by rifampin is through PXR.
Furthermore, rifampin also reduced the gene expression of
three clinically relevant drug transporters (SLC15A1, SLC22A9,
and SLCO1B3). Of these transporter, only SLCO1B3 expression
has studies evaluating rifampin regulation of gene expression.
SLCO1B3 gene expression was shown not to change in primary
hepatocytes when subjected to similar conditions (24 h 10
µM rifampin treatment; Williamson et al., 2013). Hafner et al.
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TABLE 3 | All clinically relevant drug transporters correlated with miRNA induced by rifampin with a p <0.05.
miRNA Gene Spearman correlation p-value miRNA Gene Spearman correlation p-value
Positive correlation Negative correlation
hsa-miR-200b# SLCO1B1 0.96 0.0028 hsa-miR-107 SLC16A1 −0.96 0.0028
hsa-miR-766 ABCG2 0.96 0.0028 hsa-miR-202 SLC22A9 −0.93 0.0067
hsa-miR-660 ABCB11 0.96 0.0028 hsa-miR-616 SLC22A5 −0.93 0.0067
hsa-miR-660 ABCC6 0.93 0.0067 hsa-miR-95 ABCB11 −0.93 0.0067
hsa-miR-616 ABCC5 0.89 0.012 hsa-miR-335 ABCC4 −0.93 0.0067
hsa-miR-886-3p SLC51B 0.89 0.012 hsa-miR-320 ABCC5 −0.89 0.012
hsa-miR-886-3p SLC51A 0.89 0.012 hsa-miR-638 ABCC5 −0.86 0.024
hsa-miR-766 SLCO1B1 0.86 0.024 hsa-miR-186 SLC29A2 −0.86 0.024
hsa-miR-660 SLC47A1 0.86 0.024 hsa-miR-92a ABCC4 −0.83 0.021
hsa-miR-335 SLC29A2 0.86 0.024 hsa-miR-320 ABCB11 −0.82 0.034
hsa-miR-107 SLC22A7 0.82 0.034 hsa-miR-616 SLCO1B1 −0.79 0.048
hsa-miR-660 SLCO2B1 0.82 0.034 hsa-miR-30d# SLC29A1 −0.79 0.048
hsa-miR-660 SLCO4C1 0.82 0.034 hsa-miR-95 SLC47A1 −0.79 0.048
hsa-let-7g SLC51A 0.82 0.034 hsa-miR-92a SLCO1B3 −0.76 0.049
hsa-miR-766 SLCO2B1 0.79 0.048
hsa-miR-660 ABCC2 0.79 0.048
hsa-miR-660 SLC22A1 0.79 0.048
Correlation was assessed for all miRNA tested and the 410 transporters expressed in hepatocytes. Shown in this table are the all the clinically relevant drug transporters regardless of
rifampin regulation with the miRNAs induced by rifampin with a p < 0.05. In bold, the subset of the only clinically relevant transporters whose expression was regulated by rifampin with
an FDR < 0.05 and correlated with rifampin induced miRNAs. Spearman correlation selected as samples because assumption of normal distribution could not be made.
FIGURE 4 | Illustration of the in silico ChIP-Seq testing for PXR binding sites within the 410 transporters. Rif, rifampin; TSS, Transcription Start Site.
(2011) showed no change in SLCO1B3 after 48 h of rifampicin
treatment. After 72 h of rifampin, SLCO1B3 is only moderately
elevated (Dixit et al., 2007). These studies and ours suggest
that the length of exposure to rifampin likely changes the level
of SLCO1B3 gene expression. Additionally, Williamson et al.
(2013) also showed an inhibition of SLCO1B3 expression as the
rifampin concentration increased from 0.5 to 10 µM. A possible
mechanism of this initial inhibition may be an indirect induction
of repressors that reduce drug transport gene expression through
PXR (Zhou et al., 2006; Tojima et al., 2012; Sehirli et al., 2015;
Zhang et al., 2015). Also, we must consider that rifampin is
activating other transcription factors. Another possibility may be
inhibition of drug transport gene expression through induction,
possibly through PXR of miRNAs (Ramamoorthy et al., 2013).
MicroRNAs are potentially involved in the effect rifampin
exerts on the expression of clinically relevant drug transporter
genes. For example, four transporters genes were negatively
correlated with rifampin-induced miRNA expression:
SLC47A1/miR-95, SLC29A1/miR-30d#, SLC22A9/miR-202,
and SLCO1B3/miR-92a (Table 3). Only SLCO1B3 and SLC22A9
gene expression were reduced after rifampin treatment. This was
surprising because no seed binding sites were predicted for the
rifampin-induced miRNAs in the 3′ UTRs of these transporter
genes (data not shown). Possibly, gene reduction may occur
through less well understood miRNA binding in other mRNA
regions (e.g., coding and 5′ UTR regions; Clark et al., 2014).
Rifampin’s ability to alter gene expression patterns also
demonstrated tissue specificity. Since the kidney proximal
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TABLE 4 | The 58 transporters with ChIP-Seq determined PXR binding sites.
Gene Transcript ID (Isoform) Chromosome Start of transcription start
site (TSS)
Strand Distance from the center of the PXR binding peak to
the TSS
SLC2A1 ENST00000415851 chr1 43424501 − 228.5
SLC5A9 ENST00000425816 chr1 48688357 + −1875.5
ABCD3 ENST00000394233 chr1 94883933 + −233
SLC22A15 ENST00000369503 chr1 116519119 + 884.5
ANXA9 ENST00000368947 chr1 150954493 + 97.5
ATP1B1 ENST00000367816 chr1 169074935 + 22.5
SLC30A10 ENST00000366926 chr1 220101945 − 2161.5
ANXA11 ENST00000481805 chr10 81928844 − −190.5
ABCC2 ENST00000370449 chr10 101542489 + −195
SLC25A22 ENST00000524891 chr11 795007 − −46.5
PEX16 ENST00000527371 chr11 45937095 − −2271.5
SLC43A1 ENST00000533515 chr11 57267151 − 2075
SLC3A2 ENST00000544377 chr11 62647894 + 470.5
SLCO2B1 ENST00000526839 chr11 74876919 + −884
CACNA2D4 ENST00000588896 chr12 1905116 − −248.5
SCN8A ENST00000546961 chr12 51984050 + 424
ATP2B1 ENST00000428670 chr12 90102609 − −682.5
SLC41A2 ENST00000432951 chr12 105352067 − −234.5
SCARB1 ENST00000541205 chr12 125324218 − 1402
ATP11A ENST00000487903 chr13 113344643 + −604.5
ABCA3 ENST00000563623 chr16 2390599 − −384.5
SLC5A11 ENST00000347898 chr16 24857162 + −1215.5
SLC7A5 ENST00000563489 chr16 87870412 − −1384.5
SLC25A11 ENST00000570543 chr17 4841853 − −1323.5
SLC47A1 ENST00000571335 chr17 19436775 + −62
ABCC3 ENST00000503304 chr17 48745791 + −353.5
ABCA9 ENST00000461623 chr17 67045499 − 1577.5
KCNJ2 ENST00000535240 chr17 68164814 + 1032
ATP5H ENST00000538432 chr17 73043046 − 190
MFSD11 ENST00000590070 chr17 74769179 + 2135
SLC25A10 ENST00000541223 chr17 79670404 + 87.5
SLC16A3 ENST00000582743 chr17 80186908 + 2067.5
ATP9B ENST00000590608 chr18 76886267 + −1304
SLC25A42 ENST00000318596 chr19 19174808 + −476
SLC1A4 ENST00000493121 chr2 65215611 + 1472
SLC20A1 ENST00000272542 chr2 113403434 + −488
ATP5G3 ENST00000392541 chr2 176046392 − −105.5
SLC23A2 ENST00000423430 chr20 4880294 − 887.5
SLC2A10 ENST00000359271 chr20 45338126 + 124.5
SLC5A3 ENST00000381151 chr21 35445870 + 34.5
PEX26 ENST00000329627 chr22 18560689 + −1844.5
SLC25A1 ENST00000461267 chr22 19165994 − −31.5
SCARB2 ENST00000511129 chr4 77088018 − 949
SLC39A8 ENST00000394833 chr4 103266297 − 412
SLC10A7 ENST00000507030 chr4 147442870 − −390
SLC25A4 ENST00000281456 chr4 186064395 + 15
SLC26A2 ENST00000286298 chr5 149340300 + −390
ANXA6 ENST00000522664 chr5 150484834 − 319.5
SLC39A7 ENST00000444757 chr6 33168222 + −418.5
(Continued)
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TABLE 4 | Continued
Gene Transcript ID (Isoform) Chromosome Start of transcription start
site (TSS)
Strand Distance from the center of the PXR binding peak to
the TSS
ABCC10 ENST00000372515 chr6 43395104 + 618.5
SLC29A1 ENST00000393844 chr6 44187242 + 1915
SLC17A5 ENST00000393019 chr6 74363697 − 93.5
SLC22A3 ENST00000275300 chr6 160769300 + 1939.5
ABCB4 ENST00000453593 chr7 87104782 − −315.5
SLC37A3 ENST00000340308 chr7 140098258 − -58
SLC20A2 ENST00000518717 chr8 42396198 − 194.5
ABCA2 ENST00000492260 chr9 139922624 − 1220.5
SLC25A5 ENST00000317881 chrX 118602363 + 714.5
In silico analysis utilizing a publically available HepG2 ChIP-Seq database to test the 410 transporter genes for PXR binding after rifampin treatment. Of the 410 transporter genes
analyzed, 58 transporters were found to have PXR binding sites.
tubules express transporters that may contribute to plasma
drug concentrations, we chose to study a proximal kidney cell
line to explore the effects of rifampin on clinically relevant
drug transporter gene expression. We used human proximal
tubular epithelial cells, NHPTK, because of the known role
of the proximal tubules in organic cation, anion, and drug
transport (Giacomini et al., 2010; Kido et al., 2011). This cell
line closely resembles primary proximal tubular cells with a renal
phenotype that includes, parathyroid hormone responsiveness,
tight junction formation, and transporter expression and
function (Wieser et al., 2008; Herbert et al., 2013). High
levels of drug transporter mRNA expression was detected, but
rifampin did not induce or reduce transporter expression in
a significant manner. This finding is in agreement with prior
studies evaluating rifampin effects on individual renal drug
transporters expression. For example, rifampin did not lead to
alterations in SLC22A2 expression in MDCK cells (Shu et al.,
2001). Renal gene expression of NR1I2 (PXR) is minimal in
contrast to levels observed in liver and intestine (Cheng and
Klaassen, 2006). Although renal transporter expression did not
increase with rifampin treatment, this is likely secondary to low
intracellular PXR protein concentrations. PXR appears to be a
major determinant for rifampin’s tissue selective regulation of
drug transporters.
Our study has several strengths. First, primary human
hepatocytes serve as an in-vitro system to predict changes in gene
expression patterns in the human liver. Second, RNA sequencing
allowed us to characterize all of the clinically relevant drug
transporter genes that are expressed in human liver. Third, this
approach allowed us to determine relationships between the gene
expression patterns of the clinically relevant drug transporters,
drug metabolizing enzymes, and miRNAs. Lastly, our findings
provide a blue print for future investigations exploring rifampin’s
regulation of the transporter function.
There are a few secondary issues of some importance worth
addressing. This study also produced a wealth of data on
transporters that are not yet known to be clinically relevant for
drug transport. In fact, the vast majority of ABC and SLC family
members have not yet been shown to be clinically relevant to
drug transport. The SLC superfamily is of particular interest in
drug therapeutics as it includes transporters for e.g., serotonin,
norepinephrine, and glucose that are drug targets (Gether et al.,
2006; David-Silva et al., 2013; Felts et al., 2014). SLC5A12
for instance is a sodium-coupled monocarboxylate transporter
(SMCT-2) that regulates the lactic acid levels in the blood and
has been linked to nicotine uptake (Ohkubo et al., 2012; Garnett
et al., 2013); this gene was found in our study to be highly
induced (>7-fold increase) by rifampin. Hence, our systematic
characterization of transporter gene expression provides a more
complete picture of the effects of rifampin on transporters at
large. This information can inform the selection of gene targets
for future mechanistic studies of transporter function.
Our study also has some limitations. Hepatocytes from
only 7 different individuals is not sufficient to determine
the population variability of the effects of rifampin. Using
hepatocytes from seven donors for this study should identify
the major transporters that are commonly regulated by rifampin
(Kato et al., 2005); however, there may be some transporters
that were not statistically significantly regulated by rifampin due
to the low sample number, but are in fact regulated in some
subpopulations of individuals. Another limitation is that the
impact of genetic variation on expression levels was not taken
into account. We also acknowledge that the fold-changes for the
clinically relevant drug transporter gene expression were 1.18 to
1.85-fold. However, the levels of transporter mRNA expression
have been highly correlated with their protein expression (when
protein levels were analyzed by mass spectrometry; Ohtsuki
et al., 2012; Lee et al., 2013). Also, these changes in expression
levels represent a single time point, i.e., 24 h after rifampin
treatment. Many of the correlations may not be direct, and
represent inhibition of repressors or induction of co-activators.
We also note that the ChIP-Seq dataset fromHepG2 cells may not
represent all of the PXR induction seen in primary hepatocytes,
and limiting the promoter region to ± 2 kilobases around
the TSS may have limited the detection of all PXR binding
sites.
In conclusion we identified clinically relevant drug
transporters exhibiting measurable changes that occur within a
relatively short time period after treatment with rifampin. The
coordinated changes of transporter expression by rifampin, and
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other potential inducing/repressing factors, may contribute to
transporter-mediated drug-drug interactions. The rifampin-
regulated transporters that we identified would be candidates
for further investigations to understand the mechanisms (e.g.,
direct promoter regulation by PXR, indirect effects through
miRNAs) involved in the up- and down-regulation of these
transporters. Rifampin may serve as a representative ligand of
many other PXR ligands (e.g., carbamazepine, St. John’s Wort)
may also cause effects on transporter expression similar to that
of rifampin.
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